InvestorsHub Logo
Followers 63
Posts 6424
Boards Moderated 0
Alias Born 11/25/2007

Re: pistoncity post# 39154

Saturday, 03/30/2024 8:25:59 AM

Saturday, March 30, 2024 8:25:59 AM

Post# of 39183
Maybe the CVS deal????????

01/16/2024
Annual Report - Itonis' Annual Report, ending November 30, 2023

Describe the issuers’ principal products or services.

"In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl®
product. We fulfilled various purchase orders from CVS which involved shipping Emesyl® products to two CVS
distribution centers in Texas. We had expected to gather feedback with performance metrics via an online
dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it
being “Homeopathic” and the “only fast acting nasal spray” on the market. If the success criteria are met, an
action plan will be developed by the CVS category manager to expand distribution to more of their stores, which
is typically executed in their next CVS planogram cycle. We will see what the Test & Learn Program will tell us"